Pinz Capital Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Pinz Capital Management’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-142,168	Closed	-$1.02M	–	248
2022 Q1	$1.02M	Buy	+142,168	New	+$1.51M	0.64%	58
2021 Q3	–	Sell	-1,240	Closed	-$45K	–	356
2021 Q2	$45K	Buy	+1,240	New	+$36.7K	0.01%	296

Other funds holding RXRX

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OMS

Obvious Management Services San Francisco, California $42.4M AUM 54.5% 1-Year Est. Return

DCI

Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

DOFI

DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Pinz Capital Management's RXRX Position: Q2 2022 in Review

Pinz Capital Management sold out of Recursion Pharmaceuticals (RXRX) in Q2 2022, closing a stake of 142,168 shares — an estimated $1.02M sold.

Pinz Capital Management first reported a position in RXRX in Q2 2021 and held it in 2 quarters. The position peaked at $1.02M in Q1 2022. 133 funds tracked by Wall St. Rank hold RXRX as of Q2 2022.

Pinz Capital Management reported no remaining Recursion Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Pinz Capital Management sold 142,168 Recursion Pharmaceuticals shares in Q2 2022, an estimated $1.02M.
Pinz Capital Management first reported a position in Recursion Pharmaceuticals in Q2 2021 and held it in 2 quarters.
Pinz Capital Management's Recursion Pharmaceuticals position peaked at $1.02M in Q1 2022.
133 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2022.

Based on Pinz Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.